8,300.00
+20(+0.24%)
Currency In KRW
Address
Tower 504, 13
Yongin-si, 16954
Korea, Republic of
Phone
82 70 7152 0097
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
32
First IPO Date
June 12, 2019
| Name | Title | Pay | Year Born |
| Dr. Jin Lee Soo | Chief Executive Officer | 0 | N/A |
| Dr. Hwan Moon Sung | President & CSO | 0 | N/A |
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.